Alnylam Pharmaceuticals
ALNY
#649
Rank
HK$306.74 B
Marketcap
HK$2,298
Share price
0.68%
Change (1 day)
10.02%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2026 (TTM): HK$6.78 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are HK$4.28 Billion. In 2025 the company made an earning of HK$4.96 Billion, an increase over its 2024 earnings that were of -HK$1.85 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) HK$6.78 B36.53%
2025 HK$4.96 B-369.48%
2024 -HK$1.85 Billion-24.59%
2023 -HK$2.45 Billion-67.84%
2022 -HK$7.61 Billion36.93%
2021 -HK$5.56 Billion-8.04%
2020 -HK$6.04 Billion-15.66%
2019 -HK$7.16 Billion12.23%
2018 -HK$6.38 Billion62.91%
2017 -HK$3.92 Billion17.78%
2016 -HK$3.33 Billion43.44%
2015 -HK$2.32 Billion60.69%
2014 -HK$1.45 Billion98.2%
2013 -HK$0.73 Billion
2011 -HK$0.43 Billion27.48%
2010 -HK$0.34 Billion-10.92%
2009 -HK$0.38 Billion95.77%
2008 -HK$0.2 Billion
2006 -HK$0.31 Billion-9.13%
2005 -HK$0.35 Billion34.74%
2004 -HK$0.26 Billion36.79%
2003 -HK$0.19 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Novartis
NVS
HK$123.57 B 1,714.95%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
HK$59.96 B 780.62%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
HK$40.37 B 492.97%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-HK$5.5 Billion-180.75%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-HK$0.38 Billion-105.45%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-HK$1.25 Billion-118.34%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
HK$17.78 B 161.13%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
HK$2.70 B-60.31%๐Ÿ‡บ๐Ÿ‡ธ USA